KR890008091A - L-프롤린 유도체, 이들의 제조방법 및 이들의 생물학적 사용방법 - Google Patents

L-프롤린 유도체, 이들의 제조방법 및 이들의 생물학적 사용방법 Download PDF

Info

Publication number
KR890008091A
KR890008091A KR1019880014433A KR880014433A KR890008091A KR 890008091 A KR890008091 A KR 890008091A KR 1019880014433 A KR1019880014433 A KR 1019880014433A KR 880014433 A KR880014433 A KR 880014433A KR 890008091 A KR890008091 A KR 890008091A
Authority
KR
South Korea
Prior art keywords
derivative
group
formula
proline
derivatives
Prior art date
Application number
KR1019880014433A
Other languages
English (en)
Other versions
KR0121793B1 (ko
Inventor
피에-방달 삐에르-이브
Original Assignee
챨스 에이. 쥴렌
인오르간 쏘시에떼 아노뉨 리쉐르쉬 에 데벨롭멍 파르마쉐띠끄
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 챨스 에이. 쥴렌, 인오르간 쏘시에떼 아노뉨 리쉐르쉬 에 데벨롭멍 파르마쉐띠끄 filed Critical 챨스 에이. 쥴렌
Publication of KR890008091A publication Critical patent/KR890008091A/ko
Application granted granted Critical
Publication of KR0121793B1 publication Critical patent/KR0121793B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Protection Of Transformers (AREA)
  • Measurement Of Force In General (AREA)

Abstract

내용 없음

Description

L-프롤린 유도체, 이들의 제조방법 및 이들의 생물학적 사용방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식 (I) 의 L-프롤린 유도체 및 이들 유도체의 약리학적 허용염
    상기식에서, R₁은 일반식 (II) -B의 기이며, 여기서 R은 카르보닐 라디칼 CO-, 아실 라디칼 Y-CO-또는 옥시-아실 라디칼 O-Y-CO-(Y는 C1-4의 알킬 또는 알케닐사슬임)이고 Z는 1이상의 수소원자, 그리고, 오르소 및/또는 오로소 및/또는 메타및/또는 메타및/또는 파라위치에서의 1 이상의 치환체를 나타나는데, 이들 치환체는 할로겐 원자, CF₃기, 2개의 아웃 치환체를 가지는 경우에 C1-4의 알킬 또는 알콕시 라디칼, 또는 알킬기 C1-3을 함유하는 알킬렌 디옥시기 중에서 선택하며:R₂는 NH₂또는OH라디칼, 혹은 이들 라디칼의 관능성 유도체이며: A₁ 및A₂는 동일하거나 다른 아미노산잔기이며 : B₁및B₂는 동일하거나 다른 수소원자 또는 메틸기 이다
  2. 제 1 항에 있어서, 일반식(II)의 Z가 수소원자인 것을 특징으로 하는 유도체
  3. 제 1 항에 있어서, 일반식(II)의 Z가 염소 및 불소중에서 선택한 할로겐원자, CF₃기, 두 개의 이웃 치환체를 가지는 겅우에 메톡시 및 에톡시 중에서 선택한 알콕시 라디칼, 3,4-메틸렌 및 3,4-에틸렌디옥시 중에서 선택한 알킬렌 디옥시 라디칼인 것을 특징으로 하는 유도체
  4. 제 1 항 내지 제 3 항중의 어느 한항에 있어서, 일반식 (II)의 R를 CO-, CH₂-CO-, CH₂-CH₂-CO-, CH₂-CH₂-CH₂-CO-, CH=CH-CO 또는 O-CH₂-CO-기 중에서 선택하는 것을 특징으로 하는 유도체
  5. 제 1 항 내지 제 4 항 중의 어느 한항에 있어서, A₁ 및 A₂가 천연 아미노산인데, 여기서 A₁은 글리신, L-알라닌 및 L-발린 잔기중에서 선택하며, A₂는 글리신, L-페닐 알라닌, L-히스티딘, L-로이신, L-발린 및 L-알라닌 잔기중에서 선택하는 것을 특징으로하는 유도체
  6. 시나모일-글리실- L-페닐알라닐-L-프롤린아미드, 4-플루오로시나모일-글리실 -L-페닐알라닌-L-프롤린아미드,3,4-메틸렌디옥시시나모일-글리실-L-프롤린아미드,3,4,5-트리메톡시시나모일-글리실-L-페닐알라닐-L-프로린아미드, 시나모일-글리실-L-로이실-L-프롤린아미드, 벤조일-글리실-L-페닐알라닐-L-프롤린아미드, 페닐아세틸-글리실-L-페닐알라닐-L-프롤린아미드, 및 시나모일 -글리실-L-페닐알라닐-L-3,3′-디메틸-프롤린으로 구성된 그룹으로부터 선택하는 L-프롤린 유도체
  7. 약학적 부형제와 결합하여 제 1 항 내지 제 6 항에 어느 한항에 따른 적어도 하나의 L-프롤린 유도체 유효양을 함유하는 것을 특징으로 하는 약학적 조성물
  8. 제 7 항에 있어서, 경구, 직장, 코 또는 주사에 의해 투여되는 조성물
  9. 제 7 항에 있어서, 로젠지, 정제, 젤라틴 캡슐, 드롭, 환약 또는 리포좀 형태로 투여하며, 단위용량당 1-100mg, 양호하게는 2.5-50mg 의 유효성분을 함유하는 것을 특징으로하는 약학적 조성물
  10. 제 7 항에 있어서, 조사용액으로 투여하며, 이들 주사용액은 단위 용량당 1-50mmg, 양호하게는 0.5-50mg의 L-프롤린 유도체를 함유하는 것을 특징으로 하는 약학적 조성물
  11. 제 1 항 내지 제 6 항중 어느 한 항에 따른 L-프롤린 유도체를 주성분으로 하는 생물학 시약
  12. 하기 일반식(IV)의 유도체와 하기 일반식(III)의 유도체를 반응시켜 제 1 항의 L-프롤린 유도체를 제조하는 것을 특징으로 하는 방법:
    상기식에서, B₁,B₂,A₁,A₂,R₁ 및R₂ 는 상기 정의한 바와 같다
  13. 제12항에 있어서, 하기 일반식(V)의 프롤린 유도체를 제 1 항에서 정의한 바와같은 아미노산 A₂로 응축 반응시켜 상기 일반식(III)의 유도체를 제조하는 것을 특징으로하는 방법:
    상기식에서, B₁, B₂, R₂ 및 A₂는 제 1 항에서 정의한 바와 같다
  14. 제12항 또는 제13항에 있어서, 일반식 (IV)의 R₁-A₁유도체는 R₁과 A₁의 반응 유도체를 응축시킴으로서 제조하며, 이때, 카르복실 작용기 A₁은 보호기에 의해 차단되고, 상기 응축은 강염기의 존재하에 비누화함으로서 수행되는 것을 특징으로 하는 방법
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014433A 1987-11-03 1988-11-03 L-프롤린 유도체, 이의 제조 방법 및 이를 함유하는 향정신성 생물학적 제제 KR0121793B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8715228 1987-11-03
FR8715228A FR2622581B1 (fr) 1987-11-03 1987-11-03 Nouveaux derives de l-proline, leur preparation et leurs applications biologiques

Publications (2)

Publication Number Publication Date
KR890008091A true KR890008091A (ko) 1989-07-08
KR0121793B1 KR0121793B1 (ko) 1997-11-27

Family

ID=9356437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880014433A KR0121793B1 (ko) 1987-11-03 1988-11-03 L-프롤린 유도체, 이의 제조 방법 및 이를 함유하는 향정신성 생물학적 제제

Country Status (12)

Country Link
US (1) US5212158A (ko)
EP (1) EP0316218B1 (ko)
JP (1) JP2694191B2 (ko)
KR (1) KR0121793B1 (ko)
AT (1) ATE94560T1 (ko)
CA (1) CA1340227C (ko)
DE (1) DE3884139T2 (ko)
ES (1) ES2061710T3 (ko)
FI (1) FI885083A (ko)
FR (1) FR2622581B1 (ko)
IE (1) IE64509B1 (ko)
IL (1) IL88275A0 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445606B1 (en) * 1990-02-27 1997-01-22 The Agency of Industrial Science and Technology Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides
JP3343181B2 (ja) * 1995-09-20 2002-11-11 生化学工業株式会社 桂皮酸誘導体
US7671029B2 (en) 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US20030060413A1 (en) * 2001-09-06 2003-03-27 Zimmer Robert H. Derivatives of pseudo-peptides, their preparation and their biological uses
US6908900B2 (en) * 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
DE10105040A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
US20050192228A1 (en) * 2001-02-05 2005-09-01 Jean Rapin Tripeptide derivatives for the treatment of neurodegenerative diseases
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) * 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105039A1 (de) * 2001-02-05 2002-08-08 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
US7252446B2 (en) * 2004-03-31 2007-08-07 Brother Kogoy Kabushiki Kaisha Image forming apparatus
FR2932179B1 (fr) * 2008-06-09 2012-12-07 I R D Procede microbiologique de synthese de derives cinnamoyl amides d'acides amines
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
CA2827157A1 (en) 2011-02-11 2012-08-16 Glaxosmithkline Intellectual Property Development Limited Cathepsin c inhibitors
US20160045473A1 (en) * 2012-08-01 2016-02-18 Rory Powell Blake Biological Basis Of Adult Wellness
US20150038547A1 (en) * 2013-07-31 2015-02-05 Rory Powell Blake Biological Basis of Adult Wellness

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523598A (en) * 1975-03-08 1978-09-06 Reckitt & Colmann Prod Ltd Tripeptides
US4260682A (en) * 1979-04-04 1981-04-07 Ryan James W High sensitivity assays for angiotensin converting enzyme
JPS57501234A (ko) * 1980-08-25 1982-07-15
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
JPS63112597A (ja) * 1986-10-29 1988-05-17 Tokuyama Soda Co Ltd アミノ酸誘導体
US4804743A (en) * 1987-01-29 1989-02-14 Warner-Lambert Copmany Proline-containing renin inhibitors

Also Published As

Publication number Publication date
JPH01157998A (ja) 1989-06-21
IE883321L (en) 1989-05-03
CA1340227C (fr) 1998-12-15
ES2061710T3 (es) 1994-12-16
EP0316218A1 (fr) 1989-05-17
FI885083A0 (fi) 1988-11-03
US5212158A (en) 1993-05-18
IL88275A0 (en) 1989-06-30
FR2622581A1 (fr) 1989-05-05
IE64509B1 (en) 1995-08-09
JP2694191B2 (ja) 1997-12-24
DE3884139T2 (de) 1994-05-05
FI885083A (fi) 1989-05-04
EP0316218B1 (fr) 1993-09-15
ATE94560T1 (de) 1993-10-15
KR0121793B1 (ko) 1997-11-27
FR2622581B1 (fr) 1990-02-16
DE3884139D1 (de) 1993-10-21

Similar Documents

Publication Publication Date Title
KR890008091A (ko) L-프롤린 유도체, 이들의 제조방법 및 이들의 생물학적 사용방법
US4513009A (en) Aminoacid derivatives and their therapeutic applications
KR920014828A (ko) 신규한 종양 성장-억제 소마토스타틴 동족체, 이 동족체를 함유하는 제약 조성물 및 그 제조방법
SE8302130L (sv) Farmakologiskt aktiva bifosfonater, forfarande for deras framstellning och farmaceutiska kompositioner innehallande desamma
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
KR920008065A (ko) 펩타이드 화합물, 그의 제조 방법 및 그를 함유하는 약제학적 조성물
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
DE69425431T2 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
DE68920965D1 (de) Zentralnervensystem wirksame Chromanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
KR890001965A (ko) 스퍼구알린 관련 유도체
DE69426908D1 (de) Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
FI963440A0 (fi) Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
PT85280A (fr) Procede de preparation de ](dimethylamino)-2 ethyl" ]]](methylthio)-2 phenyl"(phenylmethyl)amino"-2 oxo-2 ethyl"carbamates ou urees et de compositions pharmaceutiques les contenant
DE69015787D1 (de) Thiophenderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE69104416D1 (de) Acylbenzoxazolinone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten.
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
ATE37368T1 (de) Benzothiazolon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FI950209A (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
DK0410278T3 (da) Reninhæmmende aminooligohydroxyderivater
EA200300029A1 (ru) Новые соединения карбамат и тиокарбамат подофиллотоксина, способ их получения и содержащие их фармацевтические композиции
ES2118833T3 (es) N-(mercaptoacil)aminoacidos, metodos para su preparacion y uso terapeutico, y composiciones farmaceuticas que los contienen.
DE69011235D1 (de) Derivate von N-(Vincristinyl-23) und N-(Noranhydro-5-vinblastinyl-23) von Amino-1-methylphosphonsäure, ihre Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE69409877T2 (de) Benzospiroalken-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
RU2053228C1 (ru) Производные пептидов, способ их получения, фармацевтическая композиция, ингибирующая эластазу человеческих лейкоцитов

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
G160 Decision to publish patent application
G162 Publication of registration [patent]: decision on publication of application
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060728

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee